Europe Insulin Market Size & Outlook, 2023-2030
Europe insulin market, 2018-2030 (US$M)
Related Markets
Europe insulin market highlights
- The Europe insulin market generated a revenue of USD 4,183.2 million in 2023.
- The market is expected to grow at a CAGR of 1.6% from 2024 to 2030.
- In terms of segment, insulin analog was the largest revenue generating type in 2023.
- Insulin Analog is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Spain is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 4,183.2 million |
| Market revenue in 2030 | USD 4,664.7 million |
| Growth rate | 1.6% (CAGR from 2023 to 2030) |
| Largest segment | Insulin analog |
| Fastest growing segment | Insulin Analog |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Insulin Analog, Human Insulin |
| Key market players worldwide | Novo Nordisk A/S ADR, Eli Lilly and Co, Sanofi SA, United Laboratories International Holdings Ltd, Biocon, Wockhardt, Boehringer Ingelheim Pharma, Tonghua Dongbao Pharmaceutical, Julphar |
Other key industry trends
- In terms of revenue, Europe region accounted for 21.1% of the global insulin market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,094.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Insulin Market Scope
Insulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe insulin market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to insulin market will help companies and investors design strategic landscapes.
Insulin analog was the largest segment with a revenue share of 86.47% in 2023. Horizon Databook has segmented the Europe insulin market based on insulin analog, human insulin covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing government funding to improve healthcare infrastructure and research initiatives is expected to positively reinforce the market in Europe. For instance, nonprofit organizations such as Central European Diabetes Association (CEDA) collaborate with pharmaceutical companies for the development of innovative products.
Growing prevalence of diabetes and introduction of advanced therapeutics is expected to drive the regional market during the forecast period. The presence of opportunities available in emerging Eastern European economies is expected to fuel the market over the forecast period.
According to Diabetes UK, an estimated 4.9 million people were affected by diabetes in 2019, and 13.6 million people are currently at risk of developing type 2 diabetes in the UK. An increase in prevalence, new product launches, and rise in healthcare expenditure are expected to drive the market over the forecast period.
Reasons to subscribe to Europe insulin market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe insulin market databook
-
Our clientele includes a mix of insulin market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe insulin market , including forecasts for subscribers. This continent databook contains high-level insights into Europe insulin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe insulin market size, by country, 2018-2030 (US$M)
Europe Insulin Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
